J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Erin Furr Stimming; Victor Sung; Claudia Testa; Sandra Kostyk; Christopher A Ross; Ali Samii; Michael D Geschwind; Deborah Hall; Praveen Dayalu; Russell Lonser; Brad Elder; Paul S Larson; David L Cooper; Marcie Clarkin; Talaha M Ali; Ricardo E Dolmetsch; on behalf of the AMT-130-01 Investigators

doi:10.1136/jnnp-2022-ehdn.255

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

J: Clinical therapeutics

J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password